Company: OPGN
Filing Date: 2025-10-01
Form Type: 10-Q
Source: 0001829126-25-007819
Chunk: 1

Company: OPGEN INC
Filing Date: 2025-10-01
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
    2

    2

    Common stock, $0.01 par value; 100,000,000 shares authorized; 10,071,286 and 10,070,779 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively

    100,713

    100,708

    Additional paid-in capital

    300,862,143

    300,780,440

    Accumulated deficit

    (293,908,655
    )

    (293,500,522
    )
  
    Total stockholders’ equity

    7,054,203

    7,380,628

    Total liabilities and stockholders’ equity
     
    $
    9,418,517

    $
    9,862,698

See accompanying notes to unaudited condensed consolidated financial statements.

1

OpGen, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income

(unaudited)

    Three Months Ended March 31,

    2025

    2024

    (As Restated)

    Revenue

    Product sales
     
    $
    -

    $
    141,373

    Laboratory services

    -

    26,776

    Listing sponsorship services

    -

    -

    Total revenue

    -

    168,149

    Operating expenses

    Cost of products sold

    -

    73,236

    Cost of services

    -

    1,575

    Research and development, net

    -

    25,856

    General and administrative

    513,344

    1,684,151

    Sales and marketing

    9,502

    128,646

    Total operating expenses

    522,846

    1,913,464

    Operating loss

    (522,846
    )

    (1,745,315
    ) 

    Other income (expense)

    Interest and other income, net

    117,845

    10

    Interest expense

    (3,238
    )

    -

    Gain on impairment adjustment

    -

    2,079,575

    Change in fair value of EIB loan guaranty

    -

    (46,584
    ) 
  
    Foreign currency transaction gains

    106